Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is one of the most common, serious complications associated with pregnancy.
Venous thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, is one of the most common, serious complications associated with pregnancy, and now ranks as a leading cause of maternal morbidity and mortality in developed countries.1 Information regarding the association of VTE with acquired and heritable thrombophilias and other high-risk conditions has greatly expanded during the last 2 decades, adding a new layer of complexity to decisions about thromboprophylaxis. In addition, updated guidelines regarding VTE and pregnancy have been published recently by the Royal College of Obstetricians and Gynaecologists (RCOG), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Chest Physicians (ACCP).2-4 The objective of this review is to discuss which patients have a clinically important increased risk of VTE; of them, who needs thromboprophylaxis; and which management regimens to use in specific patient subgroups.
Mechanism of increased VTE risk in pregnancy
Pregnancy and the postpartum period carry an increased likelihood of VTE, with the frequency cited as 0.61 to 1.72 per 1,000 deliveries.5,6 Pregnant and postpartum women are thus approximately 4 to 5 times more likely to develop VTE than age-matched nonpregnant women.7 Although findings vary somewhat from study to study, roughly equal proportions of clinically apparent, pregnancy-related VTE events are diagnosed in the antepartum and postpartum periods.6 However, the frequency of VTE per unit of time (such as per week postpartum) is as much as 5 times greater postpartum than for the antepartum period.7
Severe maternal morbidity linked to mental health risks post-delivery
April 26th 2024A recent study revealed that severe maternal morbidity during pregnancy increases the likelihood of mental health hospitalizations or emergency department visits up to 13 years post-delivery, emphasizing the need for mental health screening.
Read More
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More